Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;9(2):466-476.
doi: 10.21037/tcr.2019.11.30.

Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer

Yanrong Li #  1 , Haixia Li #  1 , Baojun Yang  1 , Jing Wei  1 , Cheng Zhen  2 , Limin Feng  1
Affiliations

Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer

Yanrong Li et al. Transl Cancer Res. 2020 Feb.

Abstract

Background: The outcomes of ovarian cancer patients are very poor, therefore it is necessary to find prognostic biomarkers and explore the potential underlying molecular mechanisms of ovarian cancer.

Methods: In this study, a gene expression microarray data set covering 562 ovarian serous cystadenocarcinomas and 12,042 genes was downloaded from The Cancer Genome Atlas (TCGA) database. For each candidate gene, samples were allocated into a "high group" or a "low group" according to the expression level. The overall survival (OS) rates were compared between the two groups. Then, a univariate analysis and a multivariate Cox proportional hazards test were carried out to examine the associations between genes and multiple clinicopathological parameters.

Results: Among all candidate genes, PI3 (peptidase inhibitor 3, often called elafin) and HLA-DOB (major histocompatibility complex, class II, DO beta) were identified as hub genes. PI3 (P=7.99e-7) and HLA-DOB (P=7.52e-6) showed significant associations with OS, especially in patients with stage III or IV disease. Both PI3 (HR =1.84, P=3.77e-7) and HLA-DOB (HR =0.68, P=0.001134) were identified as independent predictors of ovarian cancer patients OS. In addition, IRF1 (interferon regulatory factor 1) (P=1.16e-15) and SPI1 (Spi-1 proto-oncogene) (P=2.03e-6) were identified as the most significant transcription factors.

Conclusions: Our data indicate that PI3 and HLA-DOB are potential biomarkers that could be used to predict the prognosis of ovarian cancer patients, and may play important roles in ovarian cancer progression. Further experimental and clinical studies with larger sample sizes are needed to confirm these findings.

Keywords: HLA-DOB; Ovarian cancer; outcome; peptidase inhibitor 3 (PI3).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.11.30). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier analysis of overall survival between low and high cases (n=562). The top row represents all the patients, then patients were grouped according to the clinical stages and curves were drawn in middle and bottom rows, respectively.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. 10.3322/caac.21551 - DOI - PubMed
    1. Torre LA, Trabert B, DeSantis CE, et al. Ovairan cancer statistics, 2018. CA Cancer J Clin 2018;68:284-96. 10.3322/caac.21456 - DOI - PMC - PubMed
    1. Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. 10.1038/nrdp.2016.61 - DOI - PMC - PubMed
    1. Escayola C, Ferron G, Romeo M, et al. The impact of pleural disease on the management of advanced ovarian cancer. Gynecol Oncol 2015;138:216-20. 10.1016/j.ygyno.2015.05.003 - DOI - PubMed
    1. Elzakkers JCJ, van der Aa MA, van Altena AM, et al. Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. Gynecol Oncol 2019. [Epub ahead of print]. 10.1016/j.ygyno.2019.08.018 - DOI - PubMed